Anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells to promote ADCC via FcγRIIIa/CD16 and complement-mediated cytotoxicity.
Humanized anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells and recruits immune effectors via its Fc to induce FcγRIIIa/CD16-mediated ADCC and complement-dependent cytotoxicity, resulting in tumor cell lysis.
NO
INDIRECT
Naxitamab binds GD2 on tumor cells; its Fc engages CD16a on NK cells to trigger ADCC (and complement), killing GD2+ tumor cells. CD16a-expressing cells serve as effectors and are not directly targeted or killed.
Anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells to promote ADCC via FcγRIIIa/CD16 and complement-mediated cytotoxicity.
Humanized anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells and recruits immune effectors via its Fc to induce FcγRIIIa/CD16-mediated ADCC and complement-dependent cytotoxicity, resulting in tumor cell lysis.
NO
INDIRECT
Naxitamab targets GD2 on tumor cells and kills them via NK cell–mediated ADCC and C1q-initiated complement-dependent cytotoxicity. C1q is an effector component, not the antigen bound by the drug, so C1q-expressing cells are not directly targeted or killed.
An antibody–drug conjugate (ADC) targeting HER2; binds HER2 on tumor cells (including HER2-low), is internalized, and releases a cytotoxic payload to kill cancer cells and disrupt HER2-driven signaling.
HER2-targeted antibody–drug conjugate; the trastuzumab-based antibody binds HER2 (including HER2-low) on tumor cells, is internalized, and a cleavable linker releases a camptothecin/topoisomerase I–inhibiting payload that induces DNA damage, inhibits replication, and triggers apoptosis, while also disrupting HER2-driven signaling.
YES
DIRECT
HER2-targeted ADC binds HER2, is internalized, and releases a camptothecin/topoisomerase I–inhibiting payload that causes DNA damage, blocks replication, and induces apoptosis in the HER2-expressing cells.
An antibody–drug conjugate (ADC) targeting HER2; binds HER2 on tumor cells (including HER2-low), is internalized, and releases a cytotoxic payload to kill cancer cells and disrupt HER2-driven signaling.
HER2-targeted antibody–drug conjugate; the trastuzumab-based antibody binds HER2 (including HER2-low) on tumor cells, is internalized, and a cleavable linker releases a camptothecin/topoisomerase I–inhibiting payload that induces DNA damage, inhibits replication, and triggers apoptosis, while also disrupting HER2-driven signaling.
NO
INDIRECT
The ADC binds HER2 on tumor cells, is internalized, and releases a camptothecin payload that inhibits topoisomerase I, causing DNA damage and apoptosis. Topoisomerase I is the intracellular enzyme target of the payload, not the cell-surface antigen used for targeting.
Humanized anti-EGFR IgG1 monoclonal antibody; blocks EGFR ligand binding, inhibiting RAS/RAF/MEK/ERK and PI3K/AKT signaling and can trigger ADCC.
Humanized IgG1 monoclonal antibody against EGFR that blocks ligand binding and receptor activation, suppressing downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling to inhibit tumor cell growth; its Fc domain can also mediate ADCC.
YES
DIRECT
Anti-EGFR IgG1 binds EGFR on target cells and its Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC; blockade of EGFR signaling also reduces survival and can induce apoptosis.